Loading patent…
AssigneesInstitut National de la Sante de la Recherche Medicale, Centre National De La Recherche Scientifique, Universite Louis Pasteur, Bristol-Myers Squibb Company
InventorsPaul Basset, Patrick Anglard, Eric Guérin
Estimating the term…
The present invention relates to methods for identifying and selecting compositions useful in differentially modulating the expression of two or more mammalian genes, particularly matrix metalloproteinase (MMP) genes such as those encoding interstitial collagenase (and other genes comprising an AP1-binding site) and stromelysin-3 (and other genes comprising a retinoic acid response element (RARE)). In addition, the invention relates to methods of treating a mammal (such as a human) suffering from or predisposed to a physical disorder, using pharmaceutical compositions comprising the compositions identified or selected by the above-described methods. The methods of the present invention are useful in treating a variety of physical disorders in mammals including cancers (particularly carcinomas), inflammatory disorders, fibrotic disorders, ocular disorders and osteoporosis.
A method of treating a mammal suffering from or predisposed to a physical disorder, comprising administering to said mammal an effective amount of a pharmaceutical composition comprising at least one retinoic acid receptor (RAR) agonist and at least one retinoid X receptor (RXR) agonist, wherein said at least one RAR agonist and said at least one RXR agonist are different compounds, and a pharmaceutically acceptable carrier or excipient therefor, wherein said composition differentially modulates the expression of a first matrix metalloproteinase gene comprising at least one AP1-binding site and a second mammalian matrix metalloproteinase gene comprising at least one retinoic acid response element (RARE).
A method of treating a mammal suffering from or predisposed to a physical disorder, comprising administering to said mammal an effective amount of a pharmaceutical composition comprising at least one RAR agonist and at least one RXR agonist, wherein said at least one RAR agonist and said at least one RXR agonist are different compounds, and a pharmaceutically acceptable carrier or excipient therefor, wherein said composition inhibits the expression of an interstitial collagenase gene in said mammal.
A method of treating a human suffering from or predisposed to a physical disorder, comprising administering to said human an effective amount of a pharmaceutical composition comprising at least one RAR agonist and at least one RXR agonist, wherein said at least one RAR agonist and said at least one RXR agonist are different compounds, and a pharmaceutically acceptable carrier or excipient therefor, wherein said composition inhibits the expression of an interstitial collagenase gene in said human.
Dependencies are inferred from the claim text.